SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
IN PARTNERSHIP WITH IQVIA
AI’s Role in Decoding the FDA’s New Regulatory Communications
In this episode of Denatured, presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses how AI transformation can help organizations navigate a rapidly evolving regulatory environment with senior director of regulatory innovation and technology, Michelle Gyzen.
June 5, 2025
 · 
1 min read
 · 
Lori Ellis
neurodegenerative diseases as Alzheimer's Disease Parkinson's Disease and Multiple Sclerosis or MS representing Huntington's Disease and Stress or anxiety and dementia as a brain disorder neurology and psychiatry symbol
Huntington’s disease
UniQure’s Regulatory Progress Sparks Optimism for ‘Desperate’ Huntington’s Space
Analysts reacted positively to the news that uniQure is in alignment with the FDA on an accelerated approval pathway and on target for a Q1 2026 submission for its one-time gene therapy for Huntington’s disease—but patients have been here before.
June 5, 2025
 · 
6 min read
 · 
Heather McKenzie
Courtesy of Sarepta Therapeutics
Gene therapy
Sarepta Wins FDA’s Platform Technology Designation, Marking ‘Critical Shift’ in Gene Therapy Development
The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug development and review process, particularly for rare diseases.
June 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Fired HHS Staff Sue RFK Jr., Musk, Claiming Terminations Were Based on ‘Error-Ridden’ Information
The lawsuit alleges that HHS leadership knew the records they used to guide their layoff decisions were inaccurate and contained errors.
June 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Halftone hands reaching for money. Mixed media catch falling coins and cash bills collage, financial success, free wealth and easy money concept vector illustration
Autoimmune disease
Cullinan Bets $700M+ in Back-Heavy China Deal for Autoimmune T Cell Engager
Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put Cullinan in a better position to target autoimmune diseases.
June 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Photo of downtown Boston from the city of Cambridge
Job Trends
Massachusetts’ Life Sciences Job Growth Flattens After 10+ Years of Increases: Report
Massachusetts’ life sciences jobs grew by just 0.03% in 2024, according to a new MassBioEd report. Still, the report found encouraging signs for the industry, noting it’s expected to grow by 11.6% by 2029, adding an estimated 16,633 net new positions.
June 4, 2025
 · 
3 min read
 · 
Angela Gabriel
Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration
Neurodegenerative disease
Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial
Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts say the outcome is unsurprising and shouldn’t affect the deal.
June 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Eli Lilly's biotechnology center in California
Obesity
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
Eli Lilly joins up with Camurus to make long-acting versions of the pharma’s obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of dosing.
June 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Rare diseases
FDA’s Prasad Vows To Make Rare Disease Drugs Available at ‘First Sign of Promise’
The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines to patients before they clear the traditional efficacy bar for authorization, Prasad said Tuesday.
June 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS